Expertise in
14
conditions

Dr. Brian Borg

Gastroenterology
Jackson Liver And GI Specialists Inc.
971 Lakeland Dr Ste 1159, 
Jackson, MS 
Expertise in
14
conditions
Jackson Liver And GI Specialists Inc.
971 Lakeland Dr Ste 1159, 
Jackson, MS 

Overview

Brian Borg is a Gastroenterologist in Jackson, Mississippi. Dr. Borg is highly rated in 14 conditions, according to our data. His top areas of expertise are Primary Biliary Cholangitis, Nonalcoholic Steatohepatitis (NASH), Cirrhosis, Liver Transplant, and Colonoscopy.

His clinical research consists of co-authoring 15 peer reviewed articles and participating in 24 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Gastroenterology

Licenses

Internal Medicine in MO

Hospital Affiliations

East Jefferson General Hospital
University Medical Center New Orleans

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Louisiana Healthcare Connections
  • HMO
  • MANAGED MEDICAID PLAN
Magnolia Health
  • HMO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Trustmark
  • PPO
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Jackson Liver and GI Specialists Inc.
971 Lakeland Dr Ste 1159, Jackson, MS 39216
Other Locations
CentraCare Digestive Center
1900 Centracare Cir Ste 2400, Saint Cloud, MN 56303

Additional Areas of Focus

Dr. Borg has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

23 Clinical Trials

A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis
A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis
Enrollment Status: Active_not_recruiting
Publish Date: February 04, 2026
Intervention Type: Drug
Study Drug: Volixibat
Study Phase: Phase 2
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
Enrollment Status: Terminated
Publish Date: December 15, 2025
Intervention Type: Drug
Study Drug: Belapectin
Study Phase: Phase 2/Phase 3
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Device, Diagnostic test
A Phase 2a, Double-Blind, Randomized, Active Controlled, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Bezafibrate Administered in Combination With Obeticholic Acid in Subjects With Primary Biliary Cholangitis
A Phase 2a, Double-Blind, Randomized, Active Controlled, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Bezafibrate Administered in Combination With Obeticholic Acid in Subjects With Primary Biliary Cholangitis
Enrollment Status: Completed
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: Bezafibrate, Obeticholic Acid
Study Phase: Phase 2
Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
Enrollment Status: Completed
Publish Date: August 11, 2025
A Two-part, Randomized, Placebo Controlled, Double Blind, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis (PBC)
A Two-part, Randomized, Placebo Controlled, Double Blind, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis (PBC)
Enrollment Status: Completed
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drug: Linerixibat
Study Phase: Phase 3
A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis
A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis
Enrollment Status: Completed
Publish Date: January 29, 2025
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 2
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
View 9 Less Clinical Trials

15 Total Publications

Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis.
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis.
Journal: Alimentary pharmacology & therapeutics
Published: July 28, 2023
Similar Doctors
Expertise in
35
conditions
Dr. Reed Hogan
Gastroenterology
Expertise in
35
conditions
Dr. Reed Hogan
Gastroenterology

Office

2510 Lakeland Dr, 
Flowood, MS 
 (940.4 miles away)
601-355-1234
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Reed Hogan is a Gastroenterologist in Flowood, Mississippi. Dr. Hogan is highly rated in 35 conditions, according to our data. His top areas of expertise are Non-Alcoholic Fatty Liver Disease, Lower Esophageal Ring, Benign Esophageal Stricture, Gastrectomy, and Gastrostomy.

Expertise in
60
conditions
Dr. Makau Lee
Gastroenterology
Expertise in
60
conditions
Dr. Makau Lee
Gastroenterology

Office

2510 Lakeland Dr, 
Flowood, MS 
 (940.4 miles away)
601-355-1234
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Makau Lee is a Gastroenterologist in Flowood, Mississippi. Dr. Lee is highly rated in 60 conditions, according to our data. His top areas of expertise are Swallowing Difficulty, Painful Swallowing, Gastrointestinal Bleeding, Endoscopy, and Gastrostomy.

Expertise in
40
conditions
Dr. Cynthia Wright
Gastroenterology
Expertise in
40
conditions
Dr. Cynthia Wright
Gastroenterology

Gastrointestinal Assoc Endoscopy

2510 Lakeland Dr, 
Flowood, MS 
 (940.4 miles away)
601-355-1234
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Cynthia Wright is a Gastroenterologist in Flowood, Mississippi. Dr. Wright is highly rated in 40 conditions, according to our data. Her top areas of expertise are Lower Esophageal Ring, Benign Esophageal Stricture, Portal Hypertension, Gastrostomy, and Endoscopy.

Frequently Asked Questions about Dr. Brian Borg

How do I make an appointment with Dr. Brian Borg?

You can book an appointment with Dr. Brian Borg by calling their office at 769-251-5674. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Brian Borg a top-rated expert for Primary Biliary Cholangitis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Brian Borg is classified as an Distinguished expert for Primary Biliary Cholangitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Brian Borg specialize in?

While Dr. Brian Borg is a Gastroenterology, they have specific expertise in Primary Biliary Cholangitis, Nonalcoholic Steatohepatitis (NASH), and Cirrhosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Brian Borg participate in research or clinical trials?

Yes. Dr. Brian Borg has published 15 articles and abstracts on conditions like Primary Biliary Cholangitis. You can view a list of Dr. Brian Borg's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Brian Borg accept my insurance?

Dr. Brian Borg accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 769-251-5674 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Borg's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 18 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile